Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2016

Open Access 01-12-2016 | Research

Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis

Authors: Lian-yuan Tao, Ling-fu Zhang, Dian-rong Xiu, Chun-hui Yuan, Zhao-lai Ma, Bin Jiang

Published in: World Journal of Surgical Oncology | Issue 1/2016

Login to get access

Abstract

Background

K-ras gene mutations are common in patients with pancreatic cancer (PC); however, their prognostic value for PC remains inconclusive. This meta-analysis was performed to quantitatively evaluate the association between K-ras mutations and survival in patients with pancreatic cancer.

Methods

We performed a comprehensive search of electronic sources including MEDLINE (via PubMed), Web of Science, and the Cochrane Library. The search covered a publication period from inception to November 2015.

Results

Seventeen studies with a total of 2249 patients with pancreatic cancer were included in the tissue detection of this study. The meta-analysis indicated a significant association between mutant K-ras genes and overall survival (OS) (HR = 1.51, 95 % CI 1.32–1.72, P < 0.001). Moreover, further subgroup analyses by ethnicity, publication year, therapy method, cancer resectability, and gene detection method all revealed that pancreatic cancer patients with the K-ras mutation had significantly poorer OS (P < 0.05). And results from four studies with 225 patients focused on plasma K-ras mutations enhanced such association (HR = 2.23, 95 % CI 1.69–2.95, P < 0.001).

Conclusions

As a prediction of poor prognosis, the detection of K-ras mutations may be a useful prognostic factor for pancreatic cancer patients.
Literature
1.
2.
Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28:645–56.CrossRefPubMed
3.
Agarwal A, Saif MW. KRAS in pancreatic cancer. JOP. 2014;15:303–5.PubMed
4.
Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44:186–98.CrossRefPubMed
5.
Fensterer H, Schade-Brittinger C, Muller HH, et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013;24:2576–81.CrossRefPubMed
6.
Schultz NA, Roslind A, Christensen IJ, et al. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas. 2012;41:759–66.PubMed
7.
Sinn BV, Striefler JK, Rudl MA, et al. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Pancreas. 2014;43:578–83.CrossRefPubMed
8.
Yin X, Su J, Zhou X, et al. K-ras-driven engineered mouse models for pancreatic cancer. Discov Med. 2015;19:15–21.PubMed
9.
Gu J, Wang D, Huang Y, et al. Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis. Int J Clin Exp. 2014;7:3225–34.
10.
Liu SL, Chen G, Zhao YP, et al. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis. Hepatobiliary Pancreat Dis Int. 2013;12:458–64.CrossRefPubMed
11.
Qin R, Smyrk TC, Reed NR, et al. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1alpha pathway to predict survival in resectable pancreatic cancer. Br J Cancer. 2015;112:514–22.CrossRefPubMedPubMedCentral
12.
Castells A, Puig P, Mora J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol. 1999;17:578–84.PubMed
13.
GA Wells SB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa score for non-randomized studies. Available at: http://​www.​ohrica/​programs/​clinical_​epidemiology/​oxfordasp 2013; Accessed December 20, 2013.
14.
15.
Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.CrossRefPubMed
16.
Allison DC, Piantadosi S, Hruban RH et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151–9.CrossRefPubMed
17.
Boeck S, Jung A, Laubender RP et al. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer 2013;108:469–76.CrossRefPubMedPubMedCentral
18.
Kim ST, Lim do H, Jang KT et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 2011;10:1993–9.
19.
Ogura T, Yamao K, Hara K et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 2013;48:640–6.CrossRefPubMed
20.
Shin SH, Kim SC, Hong SM et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 2013;42:216–22.CrossRefPubMed
21.
Franko J, Krasinskas AM, Nikiforova MN et al. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2008; 12: 1664–72; discussion 72–3.CrossRefPubMed
22.
Da Cunha Santos G, Dhani N, Tu D et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010;116:5599–607.
23.
Ikeda N, Nakajima Y, Sho M et al. The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer 2001;92:488-99.
24.
Kwon MJ, Jeon JY, Park HR et al. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value. Pancreas 2015;44:484-92.
25.
Lee J, Jang KT, Ki CS et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109:1561-9.
26.
Oh DY, Lee KW, Lee KH et al. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Invest New Drugs 2012;30:1164-74.
27.
Salek C, Minarikova P, Benesova L et al. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res 2009; 29: 1803-10.
28.
Kinugasa H, Nouso K, Miyahara K et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 2015.
29.
Talar-Wojnarowska R, Gasiorowska A, Smolarz B et al. Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis. Int J Gastrointest Cancer 2005;35:33-41.
30.
Chen H, Tu H, Meng ZQ et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol 2010;36:657-62.
31.
Yamada T, Nakamori S, Ohzato H et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clinical cancer research: an official journal of the American Association for Cancer Research 1998;4:1527-32.
32.
Dabritz J, Preston R, Hanfler J, Oettle H. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas 2009;38:534-41.
33.
Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World journal of gastroenterology 2014;20:13343-68.
34.
Miura Y, Ohnami S, Yoshida K et al. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer letters 2005;218:53-62.
Metadata
Title
Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis
Authors
Lian-yuan Tao
Ling-fu Zhang
Dian-rong Xiu
Chun-hui Yuan
Zhao-lai Ma
Bin Jiang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2016
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-016-0888-3

Other articles of this Issue 1/2016

World Journal of Surgical Oncology 1/2016 Go to the issue

Research

Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Research

The anterolateral thigh flap for soft tissue reconstruction in patients with tongue squamous cell carcinoma

Research

Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease

Case report

Thoracolumbar paravertebral giant ganglioneuroma and scoliosis: a case report and literature review

Research

Hepatocellular carcinoma on cirrhosis complicated with tumoral thrombi extended to the right atrium: results in three cases treated with major hepatectomy and thrombectomy under hypothermic cardiocirculatory arrest and literature review

Research

Prognostic factors after pulmonary metastasectomy of colorectal cancers: influence of liver metastasis